An epidemiological description of rabies outbreaks in Zambia from 2013 to 2023.

kachinda, w.; Banda, H.; Hamukale, A.; Makungu, C.; Ngoma, M.; Chazya, R.; Mataa, L.; Mulenga, C.; Banda, J. B.; Muleya, W.; Sialubanje, C.; Banda, D.; Sinyange, N.

doi:10.1101/2024.07.16.603659

bioRxiv · 10.1101/2024.07.16.603659

An epidemiological description of rabies outbreaks in Zambia from 2013 to 2023.

kachinda, w.·Banda, H.·Hamukale, A.·Makungu, C.·Ngoma, M.·Chazya, R.·Mataa, L.·Mulenga, C.·Banda, J. B.·Muleya, W.·Sialubanje, C.·Banda, D.·Sinyange, N.

View original source ↗Export metadata ↓

Abstract

BackgroundIn Zambia, a dog bite is the most common rabies exposure. There is limited information on rabies outbreaks in jackals in Zambia. We investigated all rabies cases in Zambia and narrowed down on jackal bites in Mungwi district to determine a temporal trend and buffer zones for rabies. MethodsThe risk of exposure included all humans and animals bitten by jackals, data were collected by interviewing jackal bite victims and collecting brain specimen samples from animals. Risk of spread was determined by estimating the distance jackals strayed into human population and the Rabies Vaccination Coverage (RVC) in the district. The RVC was determined by dividing vaccinated dogs by dog population. The incidence rate (IR) and a Sens slope was used to determine a trend of RVC and the rabies cases in Zambia. QGIS was used to produce a heatmap and rabies risk zones. Direct Fluorescent Antibody technique was used to test for rabies. ResultsZambia had recorded a total of 224 rabies cases with a mean (SD) of 22.4 (16) rabies cases and a positivity rate of 65.4% (25.7) per year from 2013 to 2022. Lusaka and Copperbelt provinces recorded the highest rabies cases. The rabies incidence rate was 2.3 rabies cases per 10,000 dogs in Zambia. The cases had reduced from 2013 to 2021 with a Sens slope of -0.74 (p = 0.02). At least 227 animal bites were recorded (two jackals and 225 dog bites) in Mungwi District. 94% (213) of the victims needed Post Exposure Prophylaxis. The victims median age was 20 (Interquartile range=12-38) years. The accumulative RVC from 2018-2022 (611/7777), was 0.11 (95% CI: -0.4-0.7, p=0.46) annual slope increase with 1.60% mean (Standard deviation = 0.34). One rabies heatmap and three risk-level zones (low, medium and high) were produced, and two jackals and one goat specimens were positive. ConclusionsA risk-based surveillance and enhanced vaccination of dogs in high-risk areas through a one health approach is critical for rabies control in Zambia.

Explore related subjects

pathology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

kachinda, w., Banda, H., Hamukale, A., Makungu, C., Ngoma, M., Chazya, R., Mataa, L., Mulenga, C., Banda, J. B., Muleya, W., Sialubanje, C., Banda, D., Sinyange, N.. 2024-07-18. An epidemiological description of rabies outbreaks in Zambia from 2013 to 2023.. https://doi.org/10.1101/2024.07.16.603659

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

bioRxiv2026

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗

bioRxiv2026

TREM2-stimulated, PDGF-dependent macrophage-fibroblast crosstalk induces beneficial plaque remodeling in clonal hematopoiesis

Background: In Jak2V617F clonal hematopoiesis, inflammatory signaling suppresses macrophage TREM2 and promotes features of plaque instability, while therapeutic TREM2 agonism reverses plaque instability by increasing fibroblasts and fibrous cap formation. We tested whether macrophage-derived PDGFB and stromal cell PDGFR? signaling mediate this response. Methods: Low allele burden (LAB) Jak2V617F atherosclerosis models were combined with inducible Pdgfb deletion in CX3CR1-lineage monocytes/macrophages or Pdgfra deletion in Col1a2-lineage fibroblast-enriched stromal cells. Mice were treated with the TREM2 agonist 4D9. Plaque composition, macrophage-fibroblast interactions, and aortic stromal cell populations were analyzed. Human WT and JAK2V617F iPSC-derived macrophages were used for validation. Results: TREM2 activation with 4D9 increased macrophage PDGFB production and promoted fibrous cap formation in LAB Jak2V617F atherosclerosis. Deletion of Pdgfb in CX3CR1-lineage cells markedly attenuated the 4D9-mediated increase in fibrous cap area and lesional PDGFR?+ cells, establishing macrophage-derived PDGFB as a key signal for the stromal response. Consistently, Col1a2-lineage Pdgfra deletion abolished the 4D9-induced fibrous cap response without significantly altering lesion or necrotic core area. Single cell RNA-seq identified increased Fmod+ and CD26/Dpp4+ fibroblast populations associated with 4D9 treatment. Fmod+ fibroblasts represented an abundant matrix-associated population, whereas CD26+ fibroblasts showed greatest enrichment, prominent extracellular matrix, collagen organization, and matrix-remodeling programs that were enhanced by 4D9 and attenuated by Pdgfra deletion. The stromal response was also associated with reduced macrophage migration-related programs and predicted chemokine communication from CD26+ fibroblasts to macrophages which was verified by macrophage migration studies. Moreover, stromal Pdgfra deletion increased lesional CCR2+ and CCR5+ macrophages. Conclusions: In a CH model of inflammatory atherosclerosis, TREM2 activation promotes a macrophage PDGFB-stromal PDGFR? pathway that expands Fmod+ and CD26+ fibroblast populations and increases fibrous cap matrix formation. CD26+ fibroblasts impair macrophage chemotaxis in a DPP4-dependent manner, suggesting reciprocal macrophage-fibroblast communication that coordinates matrix remodeling and inflammatory cell trafficking in the plaque.

pathology↗